US8084215B2 - Non-proteolytic method for the determination of analytes in keratinized structures - Google Patents

Non-proteolytic method for the determination of analytes in keratinized structures Download PDF

Info

Publication number
US8084215B2
US8084215B2 US12/111,914 US11191408A US8084215B2 US 8084215 B2 US8084215 B2 US 8084215B2 US 11191408 A US11191408 A US 11191408A US 8084215 B2 US8084215 B2 US 8084215B2
Authority
US
United States
Prior art keywords
analyte
sample
test solution
keratinized
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/111,914
Other languages
English (en)
Other versions
US20090269791A1 (en
Inventor
Virginia Hill
Mohammad Atefi
Michael I. Schaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psychemedics Corp
Original Assignee
Psychemedics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychemedics Corp filed Critical Psychemedics Corp
Priority to US12/111,914 priority Critical patent/US8084215B2/en
Assigned to PSYCHEMEDICS CORPORATION reassignment PSYCHEMEDICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATEFI, MOHAMMAD, HILL, VIRGINIA, SCHAFFER, MICHAEL I.
Priority to EP09739654.3A priority patent/EP2283367B1/en
Priority to BRPI0911863-2A priority patent/BRPI0911863B1/pt
Priority to PCT/US2009/042056 priority patent/WO2009134852A1/en
Priority to JP2011507600A priority patent/JP5405561B2/ja
Priority to PL09739654T priority patent/PL2283367T3/pl
Priority to CN200980125850.1A priority patent/CN102077093B/zh
Priority to CA2723161A priority patent/CA2723161C/en
Priority to US12/990,447 priority patent/US8435747B2/en
Priority to ES13170392.8T priority patent/ES2556880T3/es
Priority to HUE13170392A priority patent/HUE026327T2/en
Priority to ES09739654T priority patent/ES2430941T3/es
Priority to PL13170392T priority patent/PL2637026T3/pl
Priority to EP13170392.8A priority patent/EP2637026B1/en
Publication of US20090269791A1 publication Critical patent/US20090269791A1/en
Priority to HK14101647.9A priority patent/HK1188629A1/zh
Priority to HK11108661.8A priority patent/HK1154654A1/xx
Priority to US13/336,119 priority patent/US8329417B2/en
Publication of US8084215B2 publication Critical patent/US8084215B2/en
Application granted granted Critical
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Definitions

  • This disclosure relates to materials and methods for determining the presence and amount of one or more analytes of interest in keratinized structures of a subject, and more particularly to materials and methods for the same that do not require proteolytic processing of the keratinized structures.
  • This disclosure relates to an improved analytical method which allows the relatively rapid release and direct analysis of analytes, including organic analytes, such as certain drugs of abuse or metabolites thereof, present in hair and other keratinized structures, e.g., fingernails and toenails.
  • the method allows for the sensitive detection of such analytes without affecting the structure of the analytes and without being detrimental to analyte probes, e.g., antibody, RNA/DNA and bio-receptor probes, which may be used to detect the analyte.
  • an analyte probe can be added directly to a keratinized structure which is suspected to contain one or more analytes and which has been treated as described herein. In this way, the identity of the one or more analytes as well as the extent and duration of consumption of the one or more analytes by a subject can be evaluated.
  • Urine, blood, and oral fluid techniques are known to be disadvantageous in that the duration and intensity of use or exposure cannot be ascertained. These techniques can, at best, provide short term information concerning ingested analytes. In addition, there are also problems with the interpretation of such results. For example, the detection of a low level of ingested drug or drug metabolite in the urine could mean that a subject ingested a small amount of the drug very recently or a larger amount several days earlier. Thus, chronic drug use typically cannot be determined with these methods without repeated testing.
  • Solvent extraction procedures can suffer from several problems in accurately determining the presence and amount of an ingested analyte.
  • One of these problems is that the solvent extraction methods frequently remove only a small unknown and variable fraction of the total analyte present in the hair sample.
  • Another disadvantage is that different analytes may require different solvents or different times and temperature for extraction.
  • the solvents need to be evaporated, and many of the solvents are toxic and hazardous.
  • proteolytic and reductive treatment methods while efficient, are relatively expensive due to the cost of the proteolytic enzyme, which can also interfere in subsequent analyte detection assays by proteolytically cleaving analyte detection probes such as antibodies, thereby preventing the use of certain highly sensitive analytical techniques or requiring the use of intermediate protease neutralization, separation, or purification steps.
  • analyte detection method that can rapidly and completely release analytes from keratinized structures of the body such as hair, fingernails and toenails, and that can permit the direct determination of the identity of the analytes and their duration of use in a subject, without destroying or interfering with the analytes of interest and/or analyte detection probes such as immunoassay methods.
  • Keratinized structures such as hair are complex macroassemblies of keratin polypeptide chains that are cross-linked with numerous disulfide bonds, both intramolecularly and intermolecularly, to provide the rigidity and strength of the final structure.
  • Hair for example, is composed of coiled-coil keratin polypeptide chains that assemble to form a “protofibril;” a number of protofibrils are then bundled in a circle around two or more protofibrils to form an multi-stranded cable known as the “microfibril;” hundreds of such microfibrils taken together result in a fibrous bundle called a “macrofibril.”
  • the macrofibrils form the cortex (or the main body) layers of the hair fiber.
  • An analyte of interest can be trapped in a subject's keratinized structures as these structures grow.
  • proteolytic and reductive methods were used to fully digest and break down the keratinized structure, cleaving the keratin's proteinaceous backbone (e.g., breaking amide (peptide bond) linkages in the keratin) and reducing the intra- and intermolecular disulfide linkages to sulfhydryls, resulting in the uncoiling, unwinding, and peptidic breakage of these complex protein macrostructures.
  • the resulting method is both cost and time effective relative to prior methods, while still providing for sensitive detection of one or more analytes of interest. Moreover, the resulting method can be used in both screening and confirmatory assays for analytes of interest and, by way of example, is also compatible with immunoassay.
  • FIG. 1 sets forth a view of keratin, a protofibril comprising keratin, and a microfibril comprising protofibrils.
  • FIG. 2 demonstrates a cross-sectional view of a hair macrofibril to demonstrate how its complex macrostructure results from the assembly of microfibrils.
  • analytes are provided herein.
  • methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who previously ingested one or more of the analytes), followed by identification of the one or more analytes by known analytical techniques, including, e.g., highly sensitive receptor assays, immunoassays or instrumental techniques such as mass spectrometry or atomic absorption spectrophotometry.
  • the release of the one or more analytes into a reducing solution from the interior of the keratinized structure occurs without damaging the analyte and without causing harmful effects on a subsequently-used analyte detection probe (e.g., an antibody).
  • the methods also permit the detection of past use patterns in a subject over extended periods of time without performing repeated testing as is necessary in conventional testing methods which measure the content of the analyte in samples of blood, urine, or oral fluid.
  • the amount of analyte entrapped in hair of the same individual is directly proportional to the amount of analyte ingested, and a sectional analysis of a hair sample can provide information on historical use.
  • a sample of a keratinized structure e.g., hair
  • a subject e.g., a subject who may have ingested a particular analyte or is suspected of doing so.
  • analyte refers to any compound, whether endogenously produced or exogenously introduced in a subject.
  • an analyte of interest can be exogenously introduced in the subject, i.e., not normally present in the subject, but introduced through an exogenous method, such as via inhalation, parenteral administration (e.g., IV, transdermal, subcutaneous, or IM routes), or ingestion (e.g., oral, buccal, or transmucosal routes).
  • parenteral administration e.g., IV, transdermal, subcutaneous, or IM routes
  • ingestion e.g., oral, buccal, or transmucosal routes.
  • a metabolite or degradation product of an exogenously introduced analyte is an exogenous analyte of interest, despite the fact that it is endogenously made in vivo in a subject, because it was derived from an exogenously introduced analyte.
  • an analyte of interest can be an exogenously introduced drug-of-abuse, prescription medication, pain medication, organic compound, nutrient, metal, toxic chemical, pesticide, or a metabolite or degradation product thereof.
  • drugs of abuse, pain medications, or prescription medications, or metabolites thereof include an opioid, cannabinoid, NSAID, steroid, amphetamine, benzodiazepine, barbiturate, tricyclic, or ephedrine, or metabolite thereof.
  • cocaine and metabolites benzoylecgonine, cocaethylene, and norcocaine
  • opioids and metabolites thereof morphine, heroin, 6-monoacetylmorphine, diacetylmorphine, codeine, oxycodone, hydrocodone, hydromorphone, oxymorphone, and methadone
  • cannabinoids cannabinoids
  • PCP phencyclidine
  • amphetamines methamphetamines
  • MDMA ecstasy, methylenedioxy-methamphetamine
  • MDA methylenedioxyamphetamine
  • marijuana and THC and carboxy-THC metabolites
  • propoxyphene meperidine, benzodiazepines, carisoprodol, tramadol, fentanyl, buprenorphine, naltrexone, tricyclics, nicotine (and its metabolite cotinine), eve (methylenedioxy-ethylamphetamine), flu
  • an analyte of interest is endogenously produced, e.g., in an amount that correlates with the presence or absence of a disease state or metabolic state of a subject.
  • endogenous analytes include fatty acid esters (e.g., as markers of alcohol consumption); chromium (e.g., as measure of glucose tolerance and type 2 diabetes); glucose (e.g., as measure of glucose tolerance and type 2 diabetes); and glycosyl groups (e.g., as a measure of chronic hyperglycaemia).
  • the keratinized sample can range in size from about 4 to about 16 mg per mL of reducing agent solution, e.g., from about 5 to about 12 mg, from about 6 to about 10 mg, from about 7 to about 15 mg, from about 5 to about 10 mg, or from about 8 to about 14 mg per mL of reducing agent solution.
  • the sample can be first washed by known methods to remove analytes or contaminants which may have been deposited on the surface by external contact rather than by actual consumption.
  • the treatment method of the keratinized structure does not include contacting the keratinized structure with one or more proteolytic enzymes, such as papain, chymopapain, and proteinase K.
  • the treatment method does not proteolytically cleave peptide (amide) bonds in the structure, e.g., not cleave them substantially.
  • the method reduces, e.g., reduces substantially, disulfide bonds present in the keratinized structure sample but does not cleave peptide bonds (e.g., does not cleave them substantially) in the sample.
  • the treatment method comprises a reducing step, an optional deactivation step, and an optional purification (e.g., separation, filtration, or centrifugation) step.
  • the sample is contacted with a solution of a reducing agent (reducing solution), such as Dithiothreitol (“DTT”), so as to reduce inter- and intra-molecular disulfide bonds in the keratin macrostructure, thereby releasing entrapped analyte.
  • a reducing agent such as Dithiothreitol (“DTT”)
  • DTT Dithiothreitol
  • the keratinized structure sample can be contacted with a reducing solution consisting essentially of the reducing agent, or can be contacted with a reducing solution that does not comprise a proteolytic enzyme.
  • the contacting step does not result in the substantial breakage of peptide backbone bonds (i.e., amide bonds) in the keratin polypeptide chains.
  • the reduced keratinized structure sample can be optionally treated to deactivate residual reducing agent.
  • the deactivation step is performed in the absence of a proteolytic enzyme (e.g., in a solution consisting essentially of the deactivation agent, or in a solution that does not comprise a proteolytic enzyme).
  • a test sample can be taken from the treated keratinized structure sample, either after the contacting step with the reducing solution or after the optional deactivation step.
  • the sample can be removed directly, after the optional deactivation step, or after an optional purification step (e.g., separation, centrifugation, or filtration) to remove residual reduced keratinized sample.
  • the reducing agent for inclusion in the reducing solution can be any reducing agent capable of reducing disulfide bonds in keratinized structures.
  • Typical examples include DTT (2,3 dihydroxybutane-1,4-dithiol) or its isomer DTE (2,3 dihydroxybutane-1,4-dithiol), thioglycolate, cysteine, sulfites, bisulfites, sulfides, bisulfides or TCEP (tris(2-carboxyethyl)phosphine), or salt forms of any of the foregoing.
  • TCEP can be particularly useful in assays performed at lower pH ranges, e.g., 5.5 to about 8.
  • the concentration of the reducing agent in aqueous solution during the contacting step is about 1 to about 20 g/L, e.g., about 1 to about 15, about 2 to about 14, about 5 to about 15, about 10 to about 18, about 3 to about 12, about 4 to about 8, g/L.
  • the amount of reducing agent can vary based on the length of the reaction time and the detection methodology to be used.
  • the methods may be conducted at or near room temperature and near neutral pH.
  • the method may be performed at a temperature of between about 20° C. and 60° C. (e.g., about 20, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 60° C.) and at a pH between about pH 5 and about 10.5.
  • the pH of the method is between about 8.8 and 9.7 (e.g., 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.45, 9.5, 9.55, 9.6, 9.65) and the method occurs at a temperature of about 37° C.
  • a lower pH can be used, e.g., between about 5 to about 8.7 (e.g., about 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, or 8.7).
  • Appropriate reaction conditions including reaction temperature, time, and pH, can be readily determined by those having ordinary skill in the art. For additional information, see, e.g., U.S. Pat. Nos.
  • DTT and DTE are particularly useful as reducing agents. It has been found that the use of DTT or DTE in the described processes results in release of the entrapped analytes within a relatively short period of time (depending on the amount and type of keratinized sample), e.g., in about 0.5 to about four hours, or about 1 to about 3 hours, or about 1.5 to about 2.5 hours. In certain embodiments, treatment for about 2 hours is sufficient, e.g., for about 5-15 mg of keratinized sample such as hair.
  • residual active reducing agent can be optionally deactivated by methods known to those having ordinary skill in the art, including simply waiting a sufficient period of time for deactivation to naturally occur. Typically this time period is from about 2 to about 14 hours after initial contact of the reducing agent with the keratinized sample, depending on the concentration and amount of reducing agent utilized, the pH, temperature, size of sample, etc.
  • residual reducing agent can be deactivated with the addition of certain metal ions, typically in the form of metal salts, to the reducing solution.
  • the addition of low amounts, e.g., from about 0.1 to about 1.0 g/L in the final sample solution, of such metal salts to the reducing solution after contacting it with the sample can significantly accelerate the time in which the reduced sample can be subjected to the analyte detection method, since it is not necessary to wait for the reducing agent to deactivate on its own.
  • Most effective are certain metal salts which do not precipitate out of the solution after chemically linking with, and deactivating the reducing agent, such as DTT or DTE. It can be useful to avoid precipitation in the reducing solution because such precipitation could result in a loss of analyte by adsorption to the precipitate or entrapment therein, or could cause interference by particulate obstruction of optical reading methods.
  • precipitation is also prevented by maintaining the pH of the reducing solution from about 6 to about 8, and most preferably at about 7.
  • One way this may be accomplished is by the addition of one molar BIS-TRIS base to keep the pH at about 7.
  • a pH of about 7 is also a useful pH for the performance of certain analyte detection methods, such as radioimmunoassay (RIA) or enzyme immunoassay.
  • salts of Zn ++ e.g., zinc sulfate and zinc nitrate
  • Mn ++ e.g., manganese sulfate
  • Fe +++ e.g., ferric sulfate and ferric chloride
  • Fe ++ e.g., ferrous sulfate
  • salts of Pb ++ e.g., lead acetate and lead nitrate
  • Cd ++ e.g., cadmium chloride
  • Hg ++ e.g., mercuric chloride
  • Ag ++ e.g., silver nitrate
  • Co ++ e.g., cobalt chloride
  • a salt of arsenite such as sodium arsenite (NaAsO 2 ) may be utilized to remove residual reducing agent (e.g., DTT or DTE) by formation of a precipitable compound.
  • residual reducing agent e.g., DTT or DTE
  • 100 microliters of a 100 mg/mL solution of sodium arsenite is added to 1 mL of hair digest solution (final concentration of about 10 g/L) to effectuate the deactivation of the reducing agent.
  • arsenite is not preferred because a precipitate can develop, thereby potentially adsorbing or entrapping analyte.
  • a metal salt in solution can be added to about 0.8 to about 1.6 mL (e.g., about 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 or 1.6 mL) of reducing solution at a time period from about 1 to about 5 (e.g., about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5) hours after contacting the sample with the reducing solution.
  • the deactivation is rapidly complete, e.g., in less than about 30 minutes, such as in less than about 20 mins., less than about 10 mins., less than about 5 mins., or less than about 2 mins.
  • the reduced keratinized sample solution may be subjected to direct analysis by art recognized analyte detection methods, including receptor assays, protein-based analytical methods such as immunoassay including radioimmunoassay (RIA) or enzyme immunoassay (EIA), and/or instrumental methods such as mass spectroscopy chromatographic techniques, or atomic absorption.
  • art recognized analyte detection methods including receptor assays, protein-based analytical methods such as immunoassay including radioimmunoassay (RIA) or enzyme immunoassay (EIA), and/or instrumental methods such as mass spectroscopy chromatographic techniques, or atomic absorption.
  • instrumental methods may be used to confirm positive results obtained in immunoassay methods. Because these methods are not protein-based, the step of deactivation of reducing agent is not necessary. The speed and gentleness of the treatment method and the ability to quantitate efficiency through the inclusion of a “spike,” i.e., the inclusion of a known amount of deuterated analyte, makes the presently disclosed treatment method also the method of choice for instrumental analysis methods such as gas chromatography, liquid chromatography and mass spectrometry.
  • the method can be used to detect the use and prior use of any analyte of interest described previously, including drugs of abuse such as cocaine, morphine/heroin and other opioids, cannabinoids, marijuana, phencyclidine or “PCP,” methaqualone, and amphetamines. Moreover, the method can be effective in determining prior usage of prescription drugs such as digoxin, methadone and benzodiazepines. It is contemplated that any analyte, particularly any organic analyte, present in the bloodstream of an individual which is transferred to the hair during its synthesis can be extracted and analyzed in accordance with the methods described herein.
  • a detergent can be used to aid in the release of one or more analytes of interest.
  • Certain biological detergent compounds useful for solubilizing biological membrane components aid in the release of the analytes at a relatively low pH while not interfering with reduction or subsequent analyte detection. These biological detergents can aid the in the treatment of a keratinized sample at a pH in the range of about 5 to about 10.5.
  • Suitable detergents include bile acid detergents, such as glycocholic acid, cholic acid, taurocholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid and salts thereof, including sodium salts.
  • detergents for use in the methods are sulfo-betaines, such as the Zwittergents® and betaines, such as Empigen BB (N-dodecyl-N,N-dimethylglycine) (all available from Calbiochem Corp., La Jolla, Calif.).
  • alkylglucosides including hexyl-beta-D-glucopyranoside, heptyl-beta-D-glucopyranoside, octyl-beta-D-glucopyranoside, nonyl-beta-D-glucopyranoside, decyl-beta-D-glucopyranoside, dodecyl-beta-D-maltoside and octyl-beta-D-thioglucopyranoside (OSGP).
  • alkylglucosides including hexyl-beta-D-glucopyranoside, heptyl-beta-D-glucopyranoside, octyl-beta-D-glucopyranoside, nonyl-beta-D-glucopyranoside, decyl-beta-D-glucopyranoside, dodecyl-beta-D-maltoside and oct
  • bile acids cholic acid and glycocholic acid which aid in the digestion of hair at a pH in the range of about 6.3 to about 8.
  • the deoxycholates such as deoxycholic acid and glycodeoxycholic acid are effective in aiding in the digestion of hair at a pH above about 7.
  • the detergents can be used in the industry standard five-drug screen for the most common drugs of abuse in the United States, i.e., marijuana, cocaine, phencyclidine, methamphetamine and opioids, measured using the methods described herein. Thus, they do not impact any of the analytes or antibodies involved in the five-drug screen, and do not result in false negatives or positives.
  • the particular detergents most effective for use in the five-drug screen are cholate, deoxycholate, cholic acid, deoxycholic acid, octyl-beta-D-glucopyranoside and octyl-beta-D-thioglucopyranoside.
  • the bile acid detergents, alkylglucosides, sulfobetaines and betaines are preferred when a screen is performed that includes cocaine, opioids, phencyclidine, amphetamines and sympathomimetic amines.
  • the preferred detergents are cholic acid, Zwittergents®, alkylglucoides, and N-dodecyl-N,N dimethylglycine.
  • the biological detergent is mixed with the aqueous reducing solution prior to contact of the solution with the keratinized sample at a temperature range of about 30 to about 40° C.
  • about 1-2 mg of biological detergent is added to about 1 ml of reducing solution.
  • the benefits to be obtained from the presently disclosed methods are many, including a prompt, accurate, and inexpensive determination of prior exposure to a particular analyte.
  • the method can provide a record of consumption, or non-consumption, over very long periods of time.
  • By removal of any proteolytic treatment steps both the expense of a proteolytic method and certain interferences with biological analyte detection agents are reduced.
  • a synergistic interaction between a proteolytic enzyme and a reducing agent for diffusion of each agent into the hair structure is not required for efficient release of analytes of interest.
  • hair collection is less intrusive and less physically repulsive than blood or urine collection, and samples cannot be altered or substituted, nor can detection be evaded by short term abstention or “flushing” (excessive fluid intake) prior to a scheduled testing, e.g., pre-employment test or annual physical examination. Samples may be stored indefinitely without refrigeration.
  • the methods facilitate both screening and confirmatory assays for detecting an analyte of interest.
  • the radioimmunoassays were performed by combining aliquots of sample with I 125 -labeled drug and a primary antibody directed against the drug.
  • the labeled and unlabeled drug in the sample compete for binding sites on the primary antibody.
  • a second antibody directed against the primary antibody was added to precipitate the antibody-bound drug.
  • the precipitated bound fractions were counted in a gamma counter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
US12/111,914 2008-04-29 2008-04-29 Non-proteolytic method for the determination of analytes in keratinized structures Active 2028-08-07 US8084215B2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US12/111,914 US8084215B2 (en) 2008-04-29 2008-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
HUE13170392A HUE026327T2 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
PL13170392T PL2637026T3 (pl) 2008-04-29 2009-04-29 Nieproteolityczny sposób oznaczania analitów w strukturach skeratynizowanych
PCT/US2009/042056 WO2009134852A1 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
JP2011507600A JP5405561B2 (ja) 2008-04-29 2009-04-29 角質化構造体中の分析物を判定するためのタンパク質非分解的な方法
PL09739654T PL2283367T3 (pl) 2008-04-29 2009-04-29 Nieproteolityczny sposób oznaczania analitów w strukturach skeratynizowanych
CN200980125850.1A CN102077093B (zh) 2008-04-29 2009-04-29 用于测定角化结构中分析物的非蛋白水解方法
CA2723161A CA2723161C (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
US12/990,447 US8435747B2 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
ES13170392.8T ES2556880T3 (es) 2008-04-29 2009-04-29 Procedimiento no proteolítico de determinación de analitos en estructuras queratinizadas
EP09739654.3A EP2283367B1 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
ES09739654T ES2430941T3 (es) 2008-04-29 2009-04-29 Procedimiento no proteolítico de determinación de analitos en estructuras queratinizadas
BRPI0911863-2A BRPI0911863B1 (pt) 2008-04-29 2009-04-29 Método para determinar a presença de um analito em uma amostra de estrutura queratinizada de um indivíduo
EP13170392.8A EP2637026B1 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
HK14101647.9A HK1188629A1 (zh) 2008-04-29 2011-08-16 用於測定角質化結構中分析物的非蛋白水解方法
HK11108661.8A HK1154654A1 (en) 2008-04-29 2011-08-16 Non-proteolytic method for the determination of analytes in keratinized structures
US13/336,119 US8329417B2 (en) 2008-04-29 2011-12-23 Non-proteolytic method for the determination of analytes in keratinized structures

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/111,914 US8084215B2 (en) 2008-04-29 2008-04-29 Non-proteolytic method for the determination of analytes in keratinized structures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/336,119 Continuation US8329417B2 (en) 2008-04-29 2011-12-23 Non-proteolytic method for the determination of analytes in keratinized structures

Publications (2)

Publication Number Publication Date
US20090269791A1 US20090269791A1 (en) 2009-10-29
US8084215B2 true US8084215B2 (en) 2011-12-27

Family

ID=40749835

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/111,914 Active 2028-08-07 US8084215B2 (en) 2008-04-29 2008-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
US12/990,447 Active 2029-07-19 US8435747B2 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
US13/336,119 Active US8329417B2 (en) 2008-04-29 2011-12-23 Non-proteolytic method for the determination of analytes in keratinized structures

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/990,447 Active 2029-07-19 US8435747B2 (en) 2008-04-29 2009-04-29 Non-proteolytic method for the determination of analytes in keratinized structures
US13/336,119 Active US8329417B2 (en) 2008-04-29 2011-12-23 Non-proteolytic method for the determination of analytes in keratinized structures

Country Status (11)

Country Link
US (3) US8084215B2 (es)
EP (2) EP2637026B1 (es)
JP (1) JP5405561B2 (es)
CN (1) CN102077093B (es)
BR (1) BRPI0911863B1 (es)
CA (1) CA2723161C (es)
ES (2) ES2556880T3 (es)
HK (2) HK1154654A1 (es)
HU (1) HUE026327T2 (es)
PL (2) PL2637026T3 (es)
WO (1) WO2009134852A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104714A1 (en) * 2008-04-29 2011-05-05 Virginia Hill Non-proteolytic method for the determination of analytes in keratinized structures
US20110118138A1 (en) * 2008-04-29 2011-05-19 Virginia Hill Solid phase multi-analyte assay
US8986939B1 (en) 2013-08-28 2015-03-24 Psychemedics Corporation Integrity testing of hair samples
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5101758B1 (ja) * 2011-05-09 2012-12-19 積水メディカル株式会社 可溶性ｌｒ１１の免疫学的測定方法
CA2864526C (en) * 2012-02-14 2019-12-31 Purdue Pharma L.P. Systems and methods to quantify analytes in keratinized samples
WO2014005065A1 (en) * 2012-06-28 2014-01-03 Psychemedics Corporation Detection of analytes in hair wash samples
ITPI20130026A1 (it) * 2013-04-06 2014-10-07 Univ Pisa Metodo e dispositivo per analisi di droghe d'abuso su materiale cheratinico
CN104422607A (zh) * 2013-09-05 2015-03-18 杭州优玛达生物科技有限公司 一种毛发的前处理方法
CN103592400B (zh) * 2013-09-24 2015-07-29 广州正孚检测技术有限公司 毛发中阿片类物质的提取和检测方法
CN110044670B (zh) * 2019-03-27 2022-08-09 广州金域司法鉴定技术有限公司 毛发中毒品提取试剂盒、提取方法和检测方法
CN110987548A (zh) * 2019-10-11 2020-04-10 广州万孚生物技术股份有限公司 毛发中毒品检测方法、前处理试剂与试剂盒
AU2022222460A1 (en) 2021-02-19 2023-09-07 Imperial College Innovations Limited Lactobacillus crispatus composition for use in pregnant subjects
CN115236230B (zh) * 2022-07-21 2024-01-19 司法鉴定科学研究院 一种毛发中野生乌羽玉致幻成分麦司卡林的检测方法
CN115628951A (zh) * 2022-10-18 2023-01-20 南京火眼金睛安全科技有限公司 一种用于痕量毒品检测的人体毛发裂解液及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324642A (en) 1987-12-28 1994-06-28 Psychemedics Corporation Ligand assays of enzymatic hair digests
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US6022693A (en) 1987-12-28 2000-02-08 Psychemedics Corporation Hair analysis method
US6582924B1 (en) 1987-12-28 2003-06-24 Psychemedics Corporation Hair analysis method
US6949344B1 (en) 1987-12-28 2005-09-27 Psychemical Corporation Hair analysis method
US7252961B2 (en) 1995-02-09 2007-08-07 Dade Behring Marburg Gmbh Competitive immunoassay using complexed analyte derivatives
US7297554B2 (en) 1998-11-18 2007-11-20 Microdiagnostics, Inc. Immunoassay system
US20090269791A1 (en) 2008-04-29 2009-10-29 Psychemedics Corporation Non-proteolytic method for the determination of analytes in keratinized structures
US7618591B2 (en) * 2004-01-28 2009-11-17 Bamburgh Marrsh Llc Specimen sample collection device and test system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956467A (en) * 1988-04-01 1990-09-11 American Cyanamid Company Nucleophilic tertiary organophosphines
JP2837921B2 (ja) * 1990-05-22 1998-12-16 サイケメディクス コーポレイション 毛髪分析法
US6231982B1 (en) 1997-12-10 2001-05-15 Dade Behring Inc. Particle reagents having reduced matrix effects and containing an aldehyde-reactive functional group
JP2002504689A (ja) 1998-02-18 2002-02-12 デイド・ベーリング・インコーポレイテッド 複数の検体の検出において使用するための化学ルミネセンス組成物
JP4796259B2 (ja) 2000-05-04 2011-10-19 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 複数のアナライトの検出において使用するための組成物
US7083925B2 (en) * 2002-01-11 2006-08-01 Schnabel Robert D Method of parentage testing in North American bison, Bison bison and domestic cattle using microsatellite loci
US20040241776A1 (en) * 2003-05-22 2004-12-02 Agdia, Inc. Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
US20060166376A1 (en) 2005-01-21 2006-07-27 Craig Alan R Compositions for use as a signal generation component and methods of using same
US7629129B1 (en) * 2005-04-26 2009-12-08 The United States Of America As Represented By The Secretary Of The Army Hair follicle bulb as a biodosimeter

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324642A (en) 1987-12-28 1994-06-28 Psychemedics Corporation Ligand assays of enzymatic hair digests
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US6022693A (en) 1987-12-28 2000-02-08 Psychemedics Corporation Hair analysis method
US6350582B1 (en) 1987-12-28 2002-02-26 Psychemedics Corporation Hair analysis method
US6582924B1 (en) 1987-12-28 2003-06-24 Psychemedics Corporation Hair analysis method
US6949344B1 (en) 1987-12-28 2005-09-27 Psychemical Corporation Hair analysis method
US7252961B2 (en) 1995-02-09 2007-08-07 Dade Behring Marburg Gmbh Competitive immunoassay using complexed analyte derivatives
US7297554B2 (en) 1998-11-18 2007-11-20 Microdiagnostics, Inc. Immunoassay system
US7618591B2 (en) * 2004-01-28 2009-11-17 Bamburgh Marrsh Llc Specimen sample collection device and test system
US20090269791A1 (en) 2008-04-29 2009-10-29 Psychemedics Corporation Non-proteolytic method for the determination of analytes in keratinized structures

Non-Patent Citations (50)

* Cited by examiner, † Cited by third party
Title
"Benzodiazepines" [online]. U.S. Drug Enforcement Administration, [retrieved on Jun. 27, 2008]. Retrieved from the Internet: .
"Benzodiazepines" [online]. U.S. Drug Enforcement Administration, [retrieved on Jun. 27, 2008]. Retrieved from the Internet: <URL: http://www.usdoj.gov/dea/concern/benzodiazepines.html>.
"Dithiothreitol (DTT)," US Biological, 3 pages, Aug. 3, 2011.
"Dithiothreitol (DTT)," US Biological, 3 pages, Aug. 3, 2011.
"DL-Dithiothreitol," Product Information, Sigma-Aldrich, 1 page, Aug. 3, 2011.
"Drug Intelligence Brief, Club Drugs: An Update, Sep. 2001" [online]. U.S. Drug Enforcement Administration, 2001, [retrieved on Jun. 27, 2008]. Retrieved from the Internet (Wayback machine): .
"Drug Intelligence Brief, Club Drugs: An Update, Sep. 2001" [online]. U.S. Drug Enforcement Administration, 2001, [retrieved on Jun. 27, 2008]. Retrieved from the Internet (Wayback machine): <http://web.archive.org/web/20011120064344/http://www.usdoj.gov/dea/pubs/intel/01026/index.html>.
"Enzyme" Wikipedia.org, printed on Aug. 3, 2011 [http://en.wikipedia.org/wiki/Enzyme].
"Morphine and 6-Monoacetylmorphine in Hair of Heroin Users: Use of Invalid Extraction Procedures Generates Erroneous Conclusions," J. of Anal. Toxicology, Letter to the Editor, 29 (Jan./Feb. 2005).
"Protease" Wikipedia.org, printed on Aug. 3, 2011 [http://en.wikipedia.org/wiki/Protease].
"Proteolysis" Wikipedia.org, printed on Aug. 3, 2011 [http://en.wikipedia.org/wiki/Proteolysis].
Ahrens et al., "Detection of morphine and monoacetylmorphine (MAM) in human hair," Fresenius' Journal of Analytical Chemistry, 1992, 344(12):559-560.
Antignac et al., "Mult-residue extraction-purification procedure for corticosteroids in biological samples for efficient control of their misuse in livestock production," Journal of Chromatography B, 757: 11-19 (2001).
Authorized Officer Monika Langerova, International Search Report/Written Opinion in PCT/US09/42056 mailed Jul. 10, 2009, 10 pages.
Authorized Officer Monika Langerova, International Search Report/Written Opinion in PCT/US09/42061 mailed Sep. 15, 2009, 15 pages.
Baumgartner, "Radioimmunoassay of Hair for Determining Opiate Abuse Histories," J. Nucl. Med., 1979, 20:749-752.
Cheze et al., Analytical and Practical Aspects of Drug Testing in Hair, 2007, CRC Press, pp. 163-185.
Cleland et al., "A Specific and Sensitive Assay for Disulfides," J. of Bio. Chem, 243(4): 716-719 (1968).
Cleland, "Dithiothreitol, a New Protective Reagent for SH Groups," Biochemistry, 3(4): 480-482 (1963).
Dunnett et al., "Retrospective Detection and Deposition Profiles of Potentiated Sulphonamides in Equine Hair by Liquid Chromatography," Chromatographia, 59: S69-S78 (2004).
Dunnett et al., "Trace element, toxin and drug elimination in hair with particular reference to the horse," Res. in Vet. Science, 75: 89-101 (2003).
Gaillard et al., "Gas chromatographic-tandem mass spectrometric determination of anabolic steroids and their esters in hair: Application in doping control and meat quality control," J. of Chroma B., 735(2): 189-205 (1999).
Getz et al., "A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry," Anal. Biochem., 273: 73-80 (1999).
Gleixner et al., "Detection of the anabolic beta-2-adenoreceptor agonist clenbuterol in human scalp hair by HPLC/EIA," Clin. Chem., 1996, 42(11):1869-1871.
Gleixner, "Examination of calf hair for effective anabolic sex steroids Meaning for residue control," Fleischwirtschaft, 72(12): 1108-1110 (1997), English Translation.
Gratacos-Cubarsi et al., "Assessment of enrofloxacin and ciprofloxacin accumulation in pig and calf hair by HPLC and fluorimetric detection," Anal and Bioanalytical Chemistry; 387(6); 1991-98 (2007)vol. 387.
Gratacos-Cubarsi, et al, "Traceability of sulfonamide antibiotic treatment by immunochemical analysis of farm animal hair samples," Anal and Bioanalytical Chemistry, 395(4): 1009-16 (2009).
Gratacos-Cubarsi, et al., "Detection of sulphamethazine residues in cattle and pig hair by HPLC-DAD," J. Chrom B, 832: 121-126 (Feb. 17, 2006).
Gratacos-Cubarski et al., "Hair analysis for veterinary drug monitoring in livestock production," J. Chromatography B, 2006, 834:14-25.
Hernandez-Carrasquilla, "External contamination of bovine hair with beta2-agonist compounds: evaluation of decontamination strategies," Journal of Chromatography B, 767: 235-243 (2002).
Hernandez-Carrasquilla, "External contamination of bovine hair with β2-agonist compounds: evaluation of decontamination strategies," Journal of Chromatography B, 767: 235-243 (2002).
Hongwu et al., "Parallel Detection and Quantification Using Nine Immunoassays in a Protein Microarray for Drug from Serum Samples," Biomed. Microdev., 2005, 7(2):143-146.
Hongwu et al., "Preparation of Steroid antibodies and parallel detection of multianabolic steroid abuse with conjugated hapten microarray," Analyt. Chem., 2004, 76(20):6166-6171.
Hooijerink et al., "Liquid chromatography-electrospray ionization-mass spectrometry based method for the determination of estradiol benzoate in hair of cattle," Analytica Chimica Acta, 529:167-172 (2005).
Jouvel et al., "Detection of diazepam in horse hair samples by mass spectrometric methods," Analyst, 125: 1765-1769 (2000).
Jurado, Analytical and Practical Aspects of Drug Testing in Hair, 2007, CRC Press, pp. 95-125.
Mogos et al., "Evaluation of the metabolic balance in type 2 diabetes by assay of the hair glucose," Rom. J. Intern. Med., 2003, 41:61-65.
Nielen et al., "Multi residue screening of intact testosterone esters and boldenone undecylenate in bovine hair using liquid chromatography electrospray tandem mass spectrometry," J. Chromatography B, 2006, 830:126-134.
Offidani et al., "Improved enzymatic hydrolysis of hair," Forensic Science International, 63: 171-174 (1993).
Paisey et al., "Glycosylation of hair: possible measure of chronic hyperglycaemia," Br. Med. J. (Clin. Res. Ed.), 1984, 288:669-671.
Panoyan et al., "Immunodetection of Clenbuterol in the Hair of Calves," J. Agric. Food Chem., 43: 2716-2718 (1995).
Rambaud et al., "Study of 17beta-estradiol-3-benzoate, 17alpha-methyltestosterone and medroxyprogesterone acetate fixation in bovine hair," Analytica Chimica Acta, 532: 165-176 (2005).
Rambaud et al., "Study of 17β-estradiol-3-benzoate, 17α—methyltestosterone and medroxyprogesterone acetate fixation in bovine hair," Analytica Chimica Acta, 532: 165-176 (2005).
Staub, "Analytical procedures for determination of opiates in hair: a review," For. Sci. Int., 70: 111-123 (1995).
Stupar et al., "Longitudinal hair chromium profiles of elderly subjects with normal glucose tolerance and type 2 diabetes mellitus," Metabolism, 2007, 56(1): 94-104.
Suzuki et al., "Nails as useful materials for detection of methamphetamine or amphetamine abuse," Forensic Sci. International, 1984, 24:9-16.
Thieme et al, "Analytical strategy for detecting doping agents in hair," Forensic Science International, 107: 335-345 (2000).
Wilkins et al. "Morphine and 6-Monoacetylmorphine in Hair of Heroin Users: Use of Invalid Extraction Procedures Generates Erroneous Conclusions," J. of Analytical Toxicology, 29, 2005.
Wurst et al., "Concentration of fatty acid ethyl esters in hair of alcoholics: comparison to other biological state markers and self reported-ethanol intake," Alcohol and Alcoholism, 2004, 39:33-38.
Yegles et al., Analytical and Practical Aspects of Drug Testing in Hair, 2007, CRC Press, pp. 73-94.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104714A1 (en) * 2008-04-29 2011-05-05 Virginia Hill Non-proteolytic method for the determination of analytes in keratinized structures
US20110118138A1 (en) * 2008-04-29 2011-05-19 Virginia Hill Solid phase multi-analyte assay
US20120094309A1 (en) * 2008-04-29 2012-04-19 Psychemedics Corporation Non-proteolytic method for the determination of analytes in keratinized structures
US8329417B2 (en) * 2008-04-29 2012-12-11 Psychemedics Corporation Non-proteolytic method for the determination of analytes in keratinized structures
US8435747B2 (en) 2008-04-29 2013-05-07 Psychemedics Corporation Non-proteolytic method for the determination of analytes in keratinized structures
US10539580B2 (en) 2008-04-29 2020-01-21 Psychemedics Corporation Solid phase multi-analyte assay
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
US8986939B1 (en) 2013-08-28 2015-03-24 Psychemedics Corporation Integrity testing of hair samples
US9261522B2 (en) 2013-08-28 2016-02-16 Psychemedics Corporation Integrity testing of hair samples
EP3667325A1 (en) 2013-08-28 2020-06-17 Psychemedics Corporation Integrity testing of hair samples

Also Published As

Publication number Publication date
US20090269791A1 (en) 2009-10-29
US8329417B2 (en) 2012-12-11
PL2637026T3 (pl) 2016-03-31
US8435747B2 (en) 2013-05-07
JP5405561B2 (ja) 2014-02-05
EP2637026A1 (en) 2013-09-11
ES2430941T3 (es) 2013-11-22
BRPI0911863B1 (pt) 2023-11-28
EP2283367A1 (en) 2011-02-16
HK1154654A1 (en) 2012-04-27
HUE026327T2 (en) 2016-06-28
WO2009134852A1 (en) 2009-11-05
CN102077093A (zh) 2011-05-25
JP2011519047A (ja) 2011-06-30
CA2723161C (en) 2016-09-13
US20110104714A1 (en) 2011-05-05
BRPI0911863A2 (pt) 2015-10-13
CN102077093B (zh) 2015-03-25
US20120094309A1 (en) 2012-04-19
CA2723161A1 (en) 2009-11-05
ES2556880T3 (es) 2016-01-20
PL2283367T3 (pl) 2013-12-31
EP2283367B1 (en) 2013-06-12
EP2637026B1 (en) 2015-09-30
HK1188629A1 (zh) 2014-05-09

Similar Documents

Publication Publication Date Title
US8084215B2 (en) Non-proteolytic method for the determination of analytes in keratinized structures
EP1756575A2 (en) Detection of methamphetamine group drugs
Ramseier et al. Stereoselective screening for and confirmation of urinary enantiomers of amphetamine, methamphetamine, designer drugs, methadone and selected metabolites by capillary electrophoresis
WO1994018561A1 (en) Hair analysis method
CA2092917C (en) Hair analysis method
US6350582B1 (en) Hair analysis method
EP2623987B1 (en) Solid phase multi-analyte assay
Crooks et al. Roche DAT immunoassay: Sensitivity and specificity testing for amphetamines, cocaine, and opiates in oral fluid
Lekskulchai et al. Evaluation of Roche Abuscreen ONLINE amphetamine immunoassay for screening of new amphetamine analogues
US6582924B1 (en) Hair analysis method
US20060088896A1 (en) Diagnostic device for rapid determination of buprenorphine
Kwong Introduction to drugs of abuse testing
Schneider et al. Frontline Testing for Drugs of Abuse
Insert 6-MAM
Isenschmid et al. Analytical Considerations and Approaches for Drugs
DSC-MOR SERATEC® Drug Screen MOR

Legal Events

Date Code Title Description
AS Assignment

Owner name: PSYCHEMEDICS CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HILL, VIRGINIA;ATEFI, MOHAMMAD;SCHAFFER, MICHAEL I.;REEL/FRAME:021284/0441;SIGNING DATES FROM 20080627 TO 20080707

Owner name: PSYCHEMEDICS CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HILL, VIRGINIA;ATEFI, MOHAMMAD;SCHAFFER, MICHAEL I.;SIGNING DATES FROM 20080627 TO 20080707;REEL/FRAME:021284/0441

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12